Department of Internal Medicine, National Referral Center for Necrotizing Vasculitides and Systemic Sclerosis, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université Paris-Descartes, Paris, France.
Ann Rheum Dis. 2010 Dec;69(12):2125-30. doi: 10.1136/ard.2010.131953. Epub 2010 Jul 19.
To study the efficacy of rescue treatment strategies and outcomes in patients with Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA) not achieving remission with first-line induction with corticosteroids (CS) and intravenous cyclophosphamide (CYC).
159 eligible patients in the Wegener's Granulomatosis-Entretien (WEGENT) trial newly diagnosed with systemic or renal WG or MPA with ≥ 1 poor prognosis factors were included in this prospective study. Rescue treatment strategies and outcomes in patients with induction-refractory disease were analysed and patient characteristics at diagnosis were compared with those of induction-responders.
Most patients (n=126, 79.2%) achieved remission; 1 stopped induction because of allergy and 32 were induction-refractory (24 WG and 8 MPA); 11 died rapidly within a median of 2.5 months, 6 of uncontrolled disease, 1 of an infectious complication and 4 of both. Treatment was discontinued in 1 patient with MPA with end-stage renal disease. Induction was switched to oral CYC in 20 patients, combined with infliximab in 1; 15 (75%) achieved remission or low disease activity state, 3 subsequently died of uncontrolled disease and 2 entered remission using several other agents including biological agents. Alveolar haemorrhage and a creatinine level >200 μmol/l were independently associated with induction-refractory disease. Among patients with induction-refractory disease, massive alveolar haemorrhage was associated with higher mortality.
Switching to oral CYC can be an effective rescue treatment for patients with systemic forms of WG or MPA who fail to achieve remission with first-line CS and intravenous CYC. However, a more rapidly effective regimen remains to be identified for most severely affected patients whose outcomes can be rapidly fatal.
研究糖皮质激素(CS)和静脉环磷酰胺(CYC)一线诱导治疗未能缓解的韦格纳肉芽肿(WG)和显微镜下多血管炎(MPA)患者的挽救治疗策略和结局。
在韦格纳肉芽肿-恩蒂伦特(WEGENT)试验中,纳入了 159 名新诊断为全身或肾脏 WG 或 MPA 的患者,这些患者有≥1 个预后不良因素。分析了诱导治疗抵抗患者的挽救治疗策略和结局,并比较了诱导治疗应答者和诱导治疗抵抗者的诊断时特征。
大多数患者(n=126,79.2%)达到缓解;1 例因过敏而停止诱导治疗,32 例为诱导治疗抵抗(24 例 WG 和 8 例 MPA);11 例在中位 2.5 个月内迅速死亡,6 例死于疾病未控制,1 例死于感染并发症,4 例两者均有。1 例终末期肾病的 MPA 患者停止了治疗。20 例患者将诱导治疗转换为口服 CYC,其中 1 例联合使用英夫利昔单抗;15 例(75%)达到缓解或低疾病活动状态,3 例随后死于疾病未控制,2 例使用其他几种药物包括生物制剂进入缓解。肺泡出血和肌酐水平>200μmol/l 与诱导治疗抵抗疾病独立相关。在诱导治疗抵抗的患者中,肺泡大出血与更高的死亡率相关。
对于一线 CS 和静脉 CYC 治疗未能缓解的全身型 WG 或 MPA 患者,转换为口服 CYC 可能是一种有效的挽救治疗方法。然而,对于大多数病情严重的患者,仍需要确定更有效的治疗方案,因为这些患者的结局可能迅速致命。